Optellum, based in the TMC Innovation Institute, has entered into a partnership with Johnson & Johnson. Photo via Getty Images

Optellum, a startup whose technology helps doctors detect and treat lung cancer, has teamed up with one of the world's health care giants to broaden the software's reach.

On August 18, Optellum — whose U.S. headquarters is at Houston's TMC Innovation Institute — unveiled its new collaboration with the Lung Care Initiative at Johnson & Johnson, which racked up global sales of $82.6 billion last year. Optellum's key contribution to the partnership is its AI-powered software that aids medical professionals in detecting and treating patients with lung cancer.

With Optellum's AI-powered lung cancer diagnostics now being included in J&J's Lung Cancer Initiative, medical teams soon will enjoy access to an array of complementary technologies designed to improve diagnosis and treatment of early stage cancer. The Lung Cancer Initiative, launched in 2018 by J&J and Boston University, aims to prevent, detect, and cure lung cancer.

Lung cancer ranks as the world's most common type of cancer and leading cause of cancer deaths. About 1.8 million people around the world die from lung cancer each year. The current five-year survival rate is just 20 percent, primarily due to most patients being diagnosed after the disease has reached an advanced stage.

Optellum's Virtual Nodule Clinic software received clearance from the U.S. Food and Drug Administration (FDA) in March. Hospitals in the U.S. are rolling out the technology, with Asia-Pacific and European hospitals on track to eventually adopt the software.

The Optellum platform identifies and tracks at-risk patients, and assigns a "lung cancer prediction" score to lung nodules — small lesions, frequently detected in chest CT scans, that may or may not be cancerous.

"Optellum's vision is to redefine the early intervention of lung cancer by enabling every patient to be diagnosed and treated at the earliest possible stage, when the chances of cure are highest," the United Kingdom-based company says in a news release.

The startup — a 2019 graduate of the Texas Medical Center's accelerator — hopes to apply the technology to other lung diseases, such as chronic obstructive pulmonary disease (COPD).

Optellum recently was named one of the 101 best medical device startups in the United Kingdom. In June, the startup was among 38 AI projects chosen by the UK Department of Health and Social Care to participate in a roughly $50 million health care initiative.

Václav Potěšil, founder and CEO of Optellum, says the Johnson & Johnson collaboration represents a "significant milestone" for his company.

The J&J partnership "brings us one step closer to Optellum's vision of redefining early lung cancer treatment by helping every clinician in every hospital to make the right decisions and provide their patients the best chance to fight back," Potěšil says.

Of the 35 people employed by Optellum, three are based in the U.S. and the rest in the United Kingdom. The company's team also includes several part-time consultants, most of whom are based in the U.S. By the end of this year, Optellum plans to expand its U.S. team with several full-time hires, including a senior executive located in Houston.

Beginning next year in Houston, Optellum expects its technology to be available for patients in clinical settings.

For Potěšil, Optellum's mission is personal. He lost an aunt to lung cancer within a year of her Stage 4 diagnosis.

"I've seen firsthand how very healthy people can be killed, and it's still the most common and deadliest cancer worldwide," Potěšil is quoted as saying by the Texas Medical Center. "We are really focused on enabling cancer patients to be diagnosed at the earliest possible stage and be cured. It's not just the modeled data on the computer. It's addressing the right clinical problems to add value to doctors."

Houston can expect the new vaccine in the next week. WPA Pool / Getty Images

Here's when Houston can expect the Johnson & Johnson COVID-19 vaccine

coming soon

Texas can expect to receive the first 200,000 doses of the coveted Johnson & Johnson COVID-19 vaccine this week. The company announced that it has started the rollout process on March 1 — after the FDA approved its Emergency Use Authorization.

The Center for Disease Control gave the developer, Janssen Pharmaceutical, the final greenlight Sunday, February 28.

What does that mean for Houston? Mayor Sylvester Turner said the Houston Health Department is also anticipated to be on the list to receive Johnson & Johnson doses within the next seven days.

"That will be a game changer," Turner said at an event on February 28 afternoon. "There will be more vaccines available in a shorter period of time. We anticipate that we will probably get a shipment in sometime this week that will add to the Pfizer [doses] that we are using at NRG."

Turner said other clinics with the Houston Health Department have been administering the Moderna vaccine.

The Johnson & Johnson vaccine does have noticeable differences from the Pfizer and Moderna vaccines, experts said.

The MRNA vaccines each require two shots which are usually delivered weeks apart and stored in freezers. The Johnson & Johnson vaccine is a single shot that can be stored in a refrigerator for up to three months at 35 to 46 degrees.

However, Johnson & Johnson does not have as much of the COVID-19 vaccine produced as originally anticipated. ABC13 confirmed 3.9 million doses will be shipped out across the country this week. Johnson & Johnson announced roughly an additional 16 million doses by the end of the month.

"In the next few weeks, it won't have much of any impact because they only have at least three or four million doses available, and that's disappointing news," says Dr. Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine. "In the longer term, over the next few months, it's really important because we need a greater vaccine supply. We are not going to get there with the two MRNA vaccines. We need probably up to five different vaccines in order to vaccinate the American people."

Recently, there has been a decline in COVID-19 hospitalizations and COVID-19 cases reported statewide. As of Sunday, about 5,700 Texans are in the hospital due to COVID-19, which is half the number of hospitalization in the beginning of the month.

Infectious disease epidemiologist Dr. Catherine Troisi says it's important for people to not let their guard down and that people should get tested if they have been in a high-exposure situation, or if they have been in direct contact with someone who has tested positive.

"Get vaccinated, don't worry about what vaccine it is," Dr. Troisi notes. "It's true that unfortunately there are not as many doses right now of the Johnson & Johnson vaccine as we have hoped, but the company is saying that by the end of June, they will have a 100 million doses, and that's into 100 million people because you don't need two doses.

"So, we expect to have 600 million doses of the other two vaccines, that's 300 million people," she continues. "That should be enough for everyone who wants the vaccine to be able to get it. With one caveat and that is as of right now we do not have a vaccine for children under age 16. Those trials are going on, hopefully as we go throughout the year there will be a vaccine licensed to 12 year-olds and then maybe going down to 8 years or older."

For more details on the Johnson & Johnson vaccine rollout, visit the FDA's website.

---

This article originally ran on CultureMap. For more on this story, visit our news partner ABC13.

Tom Luby will run the Texas Medical Center's Innovation Institute. Courtesy of TMC

TMC names former JLABS leader as the director of the Innovation Institute

taking control

The Texas Medical Center didn't have to go very far to find its new Innovation Institute director. Tom Luby, who most recently served as the site head for Johnson & Johnson Innovation's JLABS @ TMC, has been hired for the position.

"I am very excited to begin the next chapter in my journey at TMC Innovation," Luby says in a release. "My time at JLABS @ TMC has shown me the tremendous opportunity there is to work with a host of talented people and companies here in Houston. Now, I'm ready to expand my role and help take TMC Innovation as a collective unit to the next level."

Luby replaces Erik Halvorsen, who left abruptly in December. According to LinkedIn, Halvorsen is now the chief business and strategy officer for Houston-based FAR Biotech, for which he previously served on the board of directors. Lance Black, associate director at TMCx, served as the director in the interim for the past few months.

Prior to JLABS, Luby was in Boston at Johnson & Johnson and served as the new ventures lead. He has 14 years of research and design experience in the Boston area.

TMC as an organization has a lot up its sleeves, says President and CEO Bill McKeon in a release, and he trusts Luby to take the lead on innovation.

"With major developments in 2018, including the announcement of the forthcoming TMC3 translational research campus, Texas Medical Center is now on the fast track to becoming the third coast for life sciences, and TMC Innovation is a critical component in the ultimate realization of this goal," says McKeon. "Tom Luby is an outstanding individual, and his proven track record working with startups in Boston and within the walls of JLABS @ TMC will serve him well as he leads us through the next evolutionary phase of the TMC Innovation Institute."

Luby will oversee the med center's accelerator program, TMCx, which is currently in the midst of its eighth cohort.

Houston has just been named an emerging life sciences hub by CBRE. The recognition took job growth and lab space into consideration for the ranking.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

3 Houston tech companies recognized for creating top inventions of the year

best of the rest

Innovations from three Houston companies have been crowned among the top inventions of the year.

Time magazine’s "200 Best Inventions of 2024" identified top innovations across consumer goods, home health, robotics, sustainability, and two dozen other categories.

Fervo Energy, a provider of geothermal power, was recognized the Green Energy category for its FervoFlex system. As Time explains, the system enables horizontal drilling into hot rock under the earth’s surface and pumping in water to generate hot water and steam. The geothermal energy that’s produced can be stored and released for future use by Fervo customers.

Jack Norbeck, Fervo’s co-founder and chief technology officer, predicts that by 2050, geothermal energy will become “the backbone of the decarbonized energy system.”

In September, Fervo secured a $100 million bridge loan for the first phase of its ongoing Cape Station project in Utah, which is being touted as the world’s largest geothermal energy plant. Slated for completion in June 2026, this initial phase is expected to generate 90 megawatts of renewable energy. Ultimately, the plant is supposed to supply 400 megawatts of clean energy by 2028 for customers in California.

Time also lauded NanoTech Materials among its Manufacturing and Materials honorees for its Insulative Ceramic Particle. This powder can be added to materials like drywall or shingles to improve fire resistance and decrease heat penetration, according to Time. NanoTech’s Wildfire Shield coating for buildings contains the powder. Wildfire Shield prevents damage to materials and harm from noxious smoke.

NanoTech’s other product, Cool Roof Coat, is painted on a building to decrease HVAC use. This year, NanoTech moved into a 43,000-square-foot space in Katy, Texas, and brought on new partners that expanded the company's reach in the Middle East and Singapore.

The third Houston company to be praised by Time is BiVACOR — named to its Experimental category of the list. This year, the company’s artificial heart has kept three U.S. patients alive long enough to wait for donor organs, according to Time, the first of these operations took place this summer in Houston.

Dr. William Cohn, chief medical officer of BiVACOR, previously told InnovationMap that while the Total Artificial Heart is being used currently as a "bridge-to-transplant" device, he believes it has the potential to be a permanent solution for the 200,000 patients who die of heart failure annually. Last year, only around 4,000 patients were able to receive heart transplants.

The full list of this year's top inventions is available online.

Houston researchers secure funding for superconductivity project

fresh funding

Researchers at the Department of Physics at the University of Houston and Texas Center for Superconductivity have received a second-year funding from global leader in business of invention Intellectual Ventures to continue their work on exploring superconductivity,

The project, which is led by Paul C. W. Chu, T.L.L. Temple Chair of Science, professor of physics and founding director of the TcSUH and assistant professor of physics and a new TcSUH principal investigator Liangzi Deng, has been awarded $767,000 to date.

“Working with IV gives us the freedom known for scientific pursuit and at the same time provides intellectual guidance and assistance in accord with the mission goal,” Chu says in a news release.

The researchers are working on making superconductivity easier to achieve. At room temperature and normal atmospheric pressure is where the researchers are looking to simplify superconductivity. One finding from Chu and Deng’s team is called pressure-quench protocol, or PQP.The PQP will help maintain key properties (like superconductivity) in certain materials after the high pressure needed to create them is removed.

“Intellectual Ventures funded this research because Paul Chu is one of the acknowledged thought leaders in the area of superconductivity with a multi-decade track record of scientific innovation and creativity,” Brian Holloway, vice president of IV’s Deep Science Fund and Enterprise Science Fund, adds. “The work led by Chu and Deng on pressure quenching could result in game-changing progress in the field. We are very excited about the preliminary results from the first year and we look forward to continuing this collaboration.”

The project showed early success the first year, as the research used a special system to synthesize materials under high temperatures and pressure. The second-year projects will include the investigation of pressure-induced/enhanced superconductivity in cuprates and hydrides.

“If successful, UH will once again break the record for the highest superconducting Tc at atmospheric pressure,” Deng says in the release. “Additionally, we will collaborate closely with theorists to uncover the mechanism of PQP. Our research has far-reaching implications, with the potential to extend beyond superconductors to other material systems.”

------

This article originally ran on EnergyCapital.

Houston expert on how you can keep your company HR compliant

guest column

Failing to remain compliant with federal and state employment laws can be costly for businesses. Doing so can lead to audits or even lawsuits.

At the same time, keeping up to date with new human resource rules and regulations may seem like a significant task, especially for small businesses focused on maintaining sufficient staffing, making payroll, keeping the lights on and building a positive culture. Companies can prevent minor mistakes from snowballing into big problems by following these tips.

Recognize the most common HR compliance mistakes

There are a few HR compliance areas where companies big and small are prone to errors. One of the most common and costly mistakes can be the incorrect classification of employees. The rules can vary significantly for full-time, part-time and contract employees when it comes to areas like benefits coverage, tax responsibilities and employment status. Failures to submit required paperwork and noncompliance with state and federal safety regulations are other common problem areas. In addition to any local or state regulations related to employment, companies should also be familiar with the requirements of the Fair Labor Standards Act (FLSA), which establishes minimum wage, overtime pay, record keeping and youth employment standards, covering employees in the private sector and in federal, state and local governments.

Support Title VII compliance

Employers and employees should be well-versed when it comes to workplace discrimination and anti-harassment laws, but they don’t just apply to managers and staff. Title VII applies to discrimination and harassment from clients, vendors and even customers. Because discrimination and harassment are often thought of as “internal workplace issues,” many companies may not be aware that they can be held responsible for the actions of non-employees when the employer (or its agents or supervisory employees) knew or should have known of inappropriate conduct and failed to take immediate and appropriate corrective action. This is why employees should be well aware of the protections in place and understand the importance of reporting harassing conduct.

Know AI-related regulations as they intersect with employment best practices

Companies are increasingly using AI in a variety of helpful ways. For instance, many employ smart software solutions to match candidates to open positions. However, these technologies can also pose a risk as they quickly evolve, along with the laws that govern them. Some AI programs may demonstrate bias to certain individuals or groups and certain cities and states are enacting legislation to prevent these kinds of issues.

Understanding varying payroll requirements

Prior to 2020, remote work options were becoming an increasingly popular benefit. The pandemic led to this option's explosive, lasting expansion. Nowadays, employees can work from other states, other times zones and even from other countries. While this is an attractive benefit to offer - especially across the technology and software sectors - there are some regulations that companies should know about.

At the top of the list are payroll laws, which can vary significantly from state to state. Employees in other states may be subject to city or state minimum wage laws or pay frequency requirements that differ from the regulations where the company headquarters is based. Overtime regulations and payroll deductions may also vary. A contracted payroll provider can help address these issues. Still, if these functions are led internally, care should be taken to stay current with the evolving regulatory landscape across the U.S.

With so many areas where mistakes can be made, companies can avoid costly errors by obtaining outside help. An employment attorney can assist in identifying and eliminating risks before they arise. Another option for small and medium-sized businesses is partnering with a professional employer organization (PEO

The rules surrounding employment in the U.S. are a moving target. This is why companies must stay up-to-speed on the various regulations that may impact their operations and be prepared to adjust as needed.

------

Fernanda Anzek is managing director of HR services with Insperity, a Houston-based provider of human resources and business performance solutions.